Webex Meeting

REGISTER HERE Join Bioverse webinar episode 8 to review the exciting presentations from AACR 2024 in San Diego. Our experts of cancer research and drug development will share will discuss: The industry-shaping data of ADC and radiopharmaceutical Clinical data from cell therapy, bispecific antibody, cancer vaccine, targeted therapy, and other drug classes Novel targets and industry-shaping scientific breakthroughs Practice-changing or market-moving clinical trial data Highlights of presentations from Asian biotech companies About the Speakers As LifeMine’s Chief Data Officer, Lihua brings vast experience in drug discovery from target identification to translational medicine, data science, and [...]

REGISTER HERE This panel of decorated physician scientists have brought about a dozen of drugs to the market and have collectively accumulated 70 years of industry drug development experience. The approved drugs (e.g., YEROVY, KEYTRUDA, ZEJULA, JEMPERLI, BLENREP, TZIELD, TREMFYA, ORENCIA, NULOJIX, FASENRA etc) span from immuno-oncology, precision-oncology, ADC, autoimmune diseases, diabetes, dermatology, to COVID, during their executive roles at Merck, JNJ, AstraZeneca, BMS, GSK, Sanofi, and a number of biotechs. Many of the biotechs were founded our panelists and later acquired by biopharmas. This is the ideal panel to share the “Checklists”, or best practice, behind this stellar [...]

REGISTER HERE Tong Zhang, PhD. Dr. Tong Zhang is the co-founder, CBO/CFO of VelaVigo. Prior to VelaVigo he was Chief Business Officer at Shanghai Genechem, Managing Director at C-Bridge Capital (CBC), a healthcare focused PE, responsible for sourcing, evaluation and execution of investment opportunities focusing on China market, as well as incubating and managing portfolio companies. Prior to CBC Tong was head of Corporate BD at WuXi AppTec, responsible for strategic partnership and M&A, head of Business Development for MSD China and pan-regional BD lead for at Merck & Co., head of Business Development at EKR Therapeutics, a [...]

REGISTER HERE

REGISTER HERE

Register Here Mr. Funtleyder has a 20-year track record of healthcare investing and is currently a Healthcare Portfolio Manager at E Squared Capital Management where he is responsible for conducting fundamental and valuation analysis of public and private companies within the healthcare industry. While at E squared Les has had five IPO exits including serving as CFO of one of the portfolio companies. Prior to E Squared, Mr. Funtleyder was the Director of Strategic Investments and Communications for Opko Health. In this role he participated in over $2 billion in transactions including acquisitions, strategic investments, and licensing deals. He [...]

REGISTER NOW Nikhil Mutyal, Ph.D. is Executive Director, Business Development and Licensing in Pacific Hub for Merck and Co (known as MSD outside of United States) based in San Francisco. Dr. Mutyal leads BD&L efforts for Oncology, Neuroscience and Cardiometabolic diseases for therapeutic opportunities from companies and research initutes based in Western US/CAN, SE Asia, ANZ. Dr. Mutyal’s professional career spans across management consulting for pharma/biotech and BD roles across various companies. Dr. Mutyal received his Ph.D. in Biomedical Engineering (Cancer Research) from Northwestern University and has B.S.+M.S. in Medicinal Chemistry from Indian Institute of Technology, [...]

Register Now Dr. Chris Sheldon is among the best biopharma dealmakers, and his impressive track record includes AstraZeneca/Daiichi's ~$13bn partnership of DS8201 and Dato-Dxd, AstraZeneca's $6.4b acquisition of Acerta over its Acalabrutinib, which is included in the sensation book "In Blood and Money", during his time at AstraZeneca as the head of Oncology BD. Shortly after he took the helm of the GSK's BD, he led the $2B acquisition of Bellus Health and also closed the deal with WuXi Biologics over their multiple bi- & multi-specific T cell engagers for oncology.

This event has ended. Please scroll down for the recording. Dr. Pearce started her career in 1997 at Hoffman-LaRoche, then at Merck launching therapeutics in the cardiovascular space. In 2001, Dr. Pearce joined a small CRO, Medpace, as a Clinical Project Manager. She led hundreds of global Phase 1-4 studies in a variety of therapeutic areas, including neurology, diabetes, lipid-lowering, kidney diseases, and obesity. She started the first business development team and marketing teams at Medpace in 2011. In 2013, Dr. Pearce joined Teva as VP, R&D, leading a new division dedicated to evaluating generics for repurposing. One of [...]

REGISTER HERE